EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen, Robert B.M. Landewé, Johannes W.J. Bijlsma, Gerd R. Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B. McInnes, Alexandre Sepriano, Ronald F. Van Vollenhoven, Maarten De Wit, Daniel Aletaha, Martin Aringer, John Askling, Alejandro Balsa, Maarten Boers, Alfons A. Den Broeder, Maya H. Buch, Frank Buttgereit, Roberto Caporali, Mario Humberto CardielDiederik De Cock, Catalin Codreanu, Maurizio Cutolo, Christopher John Edwards, Yvonne Van Eijk-Hustings, Paul Emery, Axel Finckh, Laure Gossec, Jacques Eric Gottenberg, Merete Lund Hetland, Tom W.J. Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller-Ladner, Eduardo F. Mysler, Jose A.P. Da Silva, Gyula Poór, Janet E. Pope, Andrea Rubbert-Roth, Adeline Ruyssen-Witrand, Kenneth G. Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens, Désirée Van Der Heijde
Dive into the research topics of 'EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update'. Together they form a unique fingerprint.